TODAY

今天

• 批准号: 7607048
• 负责人: DAVID M NATHAN
• 金额: $ 0.64万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7607048
• 关键词: 17 year old; Adolescent; Adult; Affect; Blood Glucose; Caring; Child; Child Care; Clinical Trials Design; Computer Retrieval of Information on Scientific Projects Database; Diagnosis; Epidemic; Funding; Grant; Institution; Insulin-Dependent Diabetes Mellitus; Metformin; Non-Insulin-Dependent Diabetes Mellitus; Obesity; Placebos; Population; Prevalence; Randomized; Range; Recruitment Activity; Relative (related person); Research; Research Personnel; Resources; Source; Today; United States National Institutes of Health; experience; lifestyle intervention; non-diabetic; troglitazone; type 2 diabetes in children

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The epidemic of obesity that has affected the entire population has not spared children and adolescents. In parallel with the increased prevalence in obesity, Type 2 diabetes has begun to be recognized in children and adolescents. Although we have long-experience in providing care for children with type 1 diabetes and adults with type 2 diabetes, there is little information regarding the means of providing care to achieve near-normal glycemia in children and adolescents with type 2 diabetes. The TODAY study is a multicenter clinical trial designed to examine several treatment options for the treatment of type 2 diabetes in children and adolescents. The study will recruit 10-17 year old children with diagnosed type 2 diabetes and randomly assign them to metformin plus a life-style intervention, troglitazone or placebo and determine the relative benefits of each in maintain in g long-term blood sugar levels as close to the non-diabetic range as possible.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 影响整个人群的肥胖症流行并未释放儿童和青少年。随着肥胖症患病率的增加，2型糖尿病已开始在儿童和青少年中识别出来。尽管我们在为患有1型糖尿病和2型糖尿病的成年人的儿童提供护理方面有很长的经验，但几乎没有关于提供护理以实现2型糖尿病儿童和青少年几乎正常血糖的方法的信息。今日研究是一项多中心临床试验，旨在检查儿童和青少年2型糖尿病的几种治疗选择。这项研究将招募10-17岁的2型糖尿病儿童，并将其随机分配给二甲双胍加上生活方式的干预，troglitazone或安慰剂，并确定每个维持在G长期血糖水平中的相对益处，尽可能接近非糖尿病范围。